Effective management of acute postoperative pain is limited by the short half-life and rapid systemic clearance of commonly used local anesthetics. The reported work evaluates a bioresponsive Quject® gel — a lyotropic liquid crystal depot designed to transition from sol to gel upon contact with biological fluids — as a platform for long-acting ropivacaine delivery to extend analgesia while reducing systemic exposure and toxicity risk.
The gel matrix investigated comprises a lipid-based system containing lecithin, Span 20, and tocopherol acetate. Formulation optimization used a ternary phase diagram approach to identify compositions that reliably and reproducibly undergo an in situ sol–gel transition on exposure to biological fluids. The intent of this design was to create an injectable liquid that forms a structured gel depot at the administration site, enabling controlled, sustained drug release from dense nanostructured channels.
Structural analysis with small-angle X-ray scattering (SAXS) and cryogenic transmission electron microscopy (cryo-TEM) confirmed the internal organization of the optimized formulation. Measurements revealed a stable reversed hexagonal phase with a lattice constant of approximately 5.80 nm. Characteristic Bragg reflections were observed at q ≈ 0.80, 1.38, and 1.60 nm⁻1 in a 1:√3:√4 ratio, consistent with hexagonal packing of aqueous channels embedded in lipid. The presence of dense, ordered nanochannels is central to the gel's mechanism for slowing ropivacaine diffusion.
The structural constraints imposed by the reversed hexagonal phase translated into markedly reduced in vitro release compared with lamellar control formulations. The hexagonal depot produced a minimal initial burst (Day-0: 3.80% of total drug) and cumulative release of 43.66% by Day-7. By contrast, lamellar control formulations released near-complete payloads (≥95%) over the same interval. These in vitro release differences reflect the impact of internal morphology on diffusion pathways and depot retention.
Pharmacokinetic profiling in rats demonstrated substantial modification of systemic exposure after subcutaneous administration of the Quject® gel loaded with ropivacaine. Key reported parameters compared with ropivacaine HCl were:
These changes indicate prolonged systemic exposure with lower peak concentrations, a profile that can maintain therapeutic levels locally while potentially mitigating peak-concentration–related systemic toxicity.
Functional efficacy was assessed using the von Frey test in a rat incision (postoperative pain) model. A single subcutaneous administration of the Quject® gel produced sustained analgesic effect for up to 72 h. By comparison, ropivacaine HCl produced analgesia lasting ≤6 h under the same model. The reported data therefore demonstrate a concordant relationship between the depot’s structural design, modified pharmacokinetics, and prolonged pain relief in vivo.
The reported pharmacokinetic profile — specifically the reduced Cmax and extended t1/2 — is presented as a means to reduce systemic toxicity risk relative to immediate-release ropivacaine formulations. The source reports the gel system as biocompatible and scalable. Details on specific safety endpoints, histopathology, local tissue tolerability, dose-ranging, and regulatory considerations were not reported in the abstract and would need to be consulted in the full text for a complete safety assessment.
This work establishes a direct structure–pharmacokinetics–efficacy relationship for a lyotropic liquid crystal Quject® gel delivering ropivacaine. The optimized reversed hexagonal morphology generated dense nanochannels that limited initial burst release and prolonged cumulative release, producing extended systemic exposure with lower peak plasma levels and sustained analgesia up to 72 h in a rat model. The authors propose this approach as a scalable, biocompatible option for prolonged postoperative analgesia. For additional experimental details, safety data, and translational plans, the full article should be consulted as the abstract does not report those specifics.
Keywords: In situ sol–gel transition; Long-acting injectable; Lyotropic liquid crystal; Postoperative pain management; ropivacaine.